局部雷珠单抗治疗角膜新生血管。
Topical ranibizumab as a treatment of corneal neovascularization.
机构信息
G.B. Bietti Eye Foundation-IRCCS, Rome, Italy.
出版信息
Cornea. 2013 Jul;32(7):992-7. doi: 10.1097/ICO.0b013e3182775f8d.
PURPOSE
To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV).
METHODS
This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA.
RESULTS
Statistically significant decreases in neovascular area (55.3%, P < 0.001), which lasted through 16 weeks, and VC (59%, P < 0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted.
CONCLUSIONS
Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.
目的
观察局部雷珠单抗对临床稳定的角膜新生血管（NV）的作用。
方法
这是一项前瞻性、开放标签、单中心、非对照非比较研究。10 只眼 9 例角膜 NV 患者接受局部雷珠单抗（1%），每天 4 次，持续 3 周，随访 16 周。主要角膜 NV 结局指标为：新生血管面积（NV 面积），即角膜新生血管所占面积；血管直径（VC），即角膜新生血管的平均直径；以及侵犯面积（IA），即被血管覆盖的角膜总面积的分数。本研究在马萨诸塞州眼耳医院进行，波士顿，MA。
结果
治疗后，NV 面积（55.3%，P<0.001）和 VC（59%，P<0.001）均呈统计学显著下降，且持续至 16 周。IA 无显著下降（12.3%，P=0.49）。视力或眼内压无统计学显著变化。未观察到与治疗相关的不良反应。
结论
雷珠单抗局部应用可有效降低已确诊角膜 NV 中 NV 的严重程度，主要通过降低 VC 而不是 IA。
Zotero 插件